Communiqués CVRx, Inc.

Actions

CVRX

US1266381052

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
11,99 ^USD	+2,48%		+10,81%	-61,86%

25/06	CVRx, Inc. annonce la nomination de Robert Allen John au poste de Chief Revenue Officer, à compter du 27 juin 2024	CI
16/05	CVRx, Inc. annonce des nominations à des postes de direction	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer	25/06	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX	07/06	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX	31/05	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX	23/05	PR
CVRx to Present at the William Blair 44th Annual Growth Stock Conference	22/05	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX	17/05	PR
CVRx Announces Key Senior Leadership Team Hires	16/05	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX	07/05	PR
CVRx: Q1 Earnings Snapshot	30/04	AQ
CVRx Reports First Quarter 2024 Financial and Operating Results	30/04	AQ
CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024	16/04	AQ
CVRx announces availability of additional data supporting long-term benefits of Barostim	15/04	AQ
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer	31/01	AQ
CVRx: Q4 Earnings Snapshot	25/01	AQ
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results	25/01	AQ
CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024	11/01	AQ
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans	08/01	AQ
CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference	27/12	AQ
CVRx receives FDA approval for expanded labeling of BarostimU.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF data	27/12	AQ
CVRx receives FDA approval for expanded labeling of Barostim	26/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués CVRx, Inc.

Actions

CVRX

US1266381052

Communiqués

Filtres